In addition, in preclinical studies, steroid-like selective ER degrader (SERD) fostered immune stimulatory activity by inhibiting suppressive myeloid cells and, in combination with anti-PD-L1 therapy, induced tumor regression and activation of anti-tumor macrophages and T cells (197). Here, CD274 is linked to neoplasm.